Interleukin-32 upregulates the expression of ABCA1 and ABCG1 resulting in reduced intracellular lipid concentrations in primary human hepatocytes by Damen, M.S.M.A. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/190130
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
Interleukin-32 upregulates the expression of ABCA1 and ABCG1
resulting in reduced intracellular lipid concentrations in primary
human hepatocytes
Michelle S.M.A. Damen a, Jessica Cristina dos Santos a, b, Rob Hermsen c,
J. Adam van der Vliet d, Mihai G. Netea a, Niels P. Riksen a, Charles A. Dinarello a, e,
Leo A.B. Joosten a, *, 1, Bas Heinhuis a, 1
a Department of Internal Medicine and Radboud Center for Infectious Diseases (RCI), Nijmegen, The Netherlands
b Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goias, Goia^nia, Brazil
c Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
d Division of Vascular and Transplant Surgery, Department of Surgery, Radboud University Medical Centre, Nijmegen, The Netherlands
e School of Medicine, Division of Infectious Diseases, University of Colorado Denver, Aurora, CO 80045, USA
a r t i c l e i n f o
Article history:
Received 23 September 2017
Received in revised form
22 January 2018
Accepted 22 February 2018
Available online 2 March 2018
Keywords:
Interleukin- (IL-) 32
Cardiovascular disease (CVD)
HDL cholesterol
Liver
Atherosclerosis
Receptors/lipoprotein
a b s t r a c t
Background and aims: The role of interleukin (IL-)32 in inﬂammatory conditions is well-established,
however, the mechanism behind its role in atherosclerosis remains unexplained. Our group reported a
promoter single nucleotide polymorphism in IL-32 associated with higher high-density lipoprotein
(HDL) concentrations. We hypothesize that endogenous IL-32 in liver cells, a human monocytic cell line
and carotid plaque tissue, can affect atherosclerosis by regulating (HDL) cholesterol homeostasis via
expression of cholesterol transporters/mediators.
Methods: Human primary liver cells were stimulated with recombinant human (rh)TNFa and poly I:C to
study the expression of IL-32 and mediators in cholesterol pathways. Additionally, IL-32 was overex-
pressed in HepG2 cells and overexpressed and silenced in THP-1 cells to study the direct effect of IL-32 on
cholesterol transporters expression and function.
Results: Stimulation of human primary liver cells resulted in induction of IL-32a, IL-32b and IL-32gmRNA
expression (p< 0.01). A strong correlation between the expression of IL-32g and ABCA1, ABCG1, LXRa
and apoA1 was observed (p< 0.01), and intracellular lipid concentrations were reduced in the presence
of endogenous IL-32 (p< 0.05). Finally, IL32g and ABCA1 mRNA expression was upregulated in carotid
plaque tissue and when IL-32 was silenced in THP-1 cells, mRNA expression of ABCA1 was strongly
reduced.
Conclusions: Regulation of IL-32 in human primary liver cells, HepG2 and THP-1 cells strongly inﬂuences
the mRNA expression of ABCA1, ABCG1, LXRa and apoA1 and affects intracellular lipid concentrations in
the presence of endogenous IL-32. These data, for the ﬁrst time, show an important role for IL32 in
cholesterol homeostasis.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Cardiovascular diseases (CVD) are currently the leading cause of
death in developed countries, with atherosclerosis as the most
important contributor to the disease burden [1,2]. Atherosclerosis is
characterized by inﬂammation and accumulation of lipids in the
vessel wall causing plaque formation [3]. Additionally, triggers such
as, smoking, hypertension, dyslipidemia and hyperglycemia, are
known to contribute to plaque formation [3e5]. Ongoing inﬂam-
mation in the plaque further activates monocytes to differentiate
into macrophages, which will take up lipids to generate foam cells.
Moreover, many studies have indicated that pro-inﬂammatory
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cytokines, including TNFa, IL-1b, IL-6, IFNg, contribute to the
development of atherosclerosis [6e8]. Recently, Heinhuis et al.
suggested that the intracellular pro-inﬂammatory cytokine inter-
leukin (IL)-32 could play an important role in atherosclerosis [9]. IL-
32 has been shown to play a role in inﬂammatory diseases with an
increased risk for CVD, such as rheumatoid arthritis (RA) and hu-
man immunodeﬁciency virus (HIV) [10e13]. IL-32 can be spliced
into various isoforms with IL-32a, IL-32b and IL-32g being most
intensively studied and IL-32g being the most active isoform [14].
In atherosclerotic plaques, IL32 is expressed, and in macrophages,
IL32 overexpression increases the expression of chemokine (C-C
motif) ligand 2 (CCL2), soluble vascular cell adhesion molecule
(sVCAM-1), matrix metalloproteinase 1 (MMP1), MMP9, and
MMP13. IL-32 promotes inﬂammation by induction of pro-
inﬂammatory cytokines like TNFa, IL-6, IL-1b and IL-8 [15,16].
Furthermore, IL-32 seems to be a regulator of endothelial cell
function where it enhances IL-1b-induced intracellular adhesion
molecule 1 (ICAM-1) [17].
In contrast to these pro-atherogenic actions, IL32 could also
have anti-atherosclerotic effects by increased HDL cholesterol [18].
Recently, a promoter single nucleotide polymorphism (SNP) in IL32
was found to be associated with HDL cholesterol (HDLc) concen-
trations in both RA patients as well as individuals with an increased
CVD risk, again suggesting a role for IL-32 in CVD [18]. Individuals
homozygous for the C- allele showed higher HDLc concentrations
compared to individuals being heterozygous or homozygous for the
T-allele. HDLc is considered to be atheroprotective even though
Mendelian randomization studies and drug trials showed there is
no causality dependent on HDL cholesterol levels but rather athe-
roprotective HDL functions are more relevant metrics to analyze
[19,20]. Therefore, IL32 could still have an atheroprotective role.
The HDLmetabolism starts in the liver, which is an important organ
in HDL biosynthesis and a regulator of plasma HDL concentrations.
Additionally, the small intestine, and especially enterocytes are
involved in biosynthesis of HDLc. Dietary lipids including choles-
terol esters and triacylglycerols are ﬁrst hydrolyzed in the inter-
stitial lumen of the intestine after which the products are taken up
by enterocytes [21]. These products are re-synthesized by enter-
ocytes and packed into either chylomicrons or HDLc for secretion
into the circulation. Moreover, the biosynthesis of HDL involves
synthesis and secretion of apolipoproteins (apoA-I and apoA-II)
followed by acquisition of lipids and generation of mature HDL
[22,23]. Lipidation of nascent, discoidal apoA-I containing HDL
particles must occur to form mature HDL. A critical participant
herein is the ATP-binding cassette A1 (ABCA1) expressed on liver
cells and enterocytes. These nascent, discoidal apoA-I containing
HDL particles are secreted via hepatic and enterocyte ABCA1 and
are matured in circulation via the lecithine-cholesterol-
acyltransferase (LCAT) function and formation of spherical HDL
particles [24]. In the absence of ABCA1, extremely low levels of
HDLc and apoA-I are observed, which contribute to an increased
risk for CVD.
An important mechanism involved in regulation of excessive
cholesterol is reverse cholesterol transport (RCT). During RCT,
excessive cholesterol is transferred from peripheral tissues and the
arterial wall back to the liver for removal from the body [25,26].
This cholesterol efﬂux is also mediated via ABCA1, which is induced
by activation of liver X receptor alpha (LXRa) [27e29]. Alternatively,
ABCG1 transports excessive cholesterol outside the cells [30,31].
Upon return to the liver, HDLc can be taken up by scavenger re-
ceptor class B, type 1 (SR-B1) for degradation of HDL. Another
alternative pathway, by which HDLc is metabolized and trans-
ported to the liver, is via the cholesteryl ester (CE) transfer protein
(CETP). Knowing the effect of IL-32 on HDLc concentrations and the
importance of the role of the liver in HDLc and cholesterol efﬂux,
one can argue a role for IL-32 in HDLc metabolism and synthesis in
liver cells. However, despite previous studies on the role of IL-32 in
cardiovascular disease, studies investigating the exact mechanism
of how IL-32 inﬂuences cholesterol homeostasis remain scarce. The
present study aims to investigate the precise role of IL-32 on HDLc
homeostasis, focussing on cholesterol transporters involved in this
process in human primary liver cells and the human monocytic cell
line THP1.
2. Materials and methods
2.1. Culturing primary human liver cells, HepG2 and THP-1 cell lines
and carotid artery plaque tissue
Patients undergoing liver surgery in our hospital donated hu-
man liver tissue. The anonymized liver tissue was used to isolate
primary human liver cells as previously reported [32]. Human liver
cells were seeded in Williams B medium containing 10% human
serum and penicillin/streptomycin. This study (2014-1453) was
reported and approved by our ethical committee of the Radboud
University Medical Center. The human liver cell line HepG2 was
cultured in complete Dulbecco's Modiﬁed Eagle's Medium with
glutamax (Gibco) containing 10% heat-inactivated Fetal Calfs Serum
(FCS), pyruvate (Gibco) and gentamycin (Gibco). Trypsin was used
to detach the adherent cells and the cell line was passaged twice a
week in a 1:5 ratio.
The human monocytic cell line THP1 was used to study over-
expression and silencing of IL-32 and its effect on cholesterol
transporters. The cell line was cultured in Roswell Park Memorial
Institute (RPMI) 1640medium containing heat-inactivated 10% FCS,
pyruvate and gentamycin. Cells were growing in suspension and
passaged twice a week in fresh medium.
Fresh carotid artery plaque tissue was kindly provided by the
department of surgery from the Radboud University Medical Cen-
ter, and upon arrival was separated into 4 pieces to perform various
analyses. Samples were then stored at 80 C for further use.
2.2. Quantitative PCR
Human primary liver cells were seeded ~200,000 cells per well
in a 24 well plate in 0.5ml Williams B medium containing 10%
human serum and penicillin/streptomycin. The next day, cells were
stimulatedwith TNFa (100 ng/ml) (R&D Systems) or Poly I:C (50 mg/
ml) (Invivogen) for 24 h. Subsequently, medium was removed and
stored and 0.5ml Tri-reagent (Sigma-Aldrich) was added per well.
After lysing the cells by incubating them with Tri-reagent for
30min at room temperature, the solution containing lysed cells
werewas stored at20 C until further processing. HepG2 cells and
THP-1 cells were lysed in TriZol reagent and also stored for later
use. Carotid artery tissue was crushed in TriZol reagent using
Magnalyser green beads (Roche). RNA was isolated as previously
described [33]. After RNA isolation, mRNA was transformed into
cDNA by applying an iScript kit (Bio-Rad) to transform mRNA into
cDNA. IL-32 primers were previously developed and other primer
sequences were extracted from the Harvard Primerbank database
[34]. Primers were produced by Biolegio (Nijmegen, The
Netherlands) and a StepOnePlus qPCR system (Applied Biosystems)
was used to analyze relative mRNA expression. Relative expression
was calculated by normalizing for GAPDH and 2DCt method.
2.3. Western blotting
Twenty-four hours after stimulation, primary liver cells were
washed with PBS and lysed with standard cell lysis buffer on ice for
30min. Subsequently, cells were scraped with a cell scraper and
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transferred into a safe-lock tube. Proteins were boiled in Laemmli
buffer under denaturing and reducing conditions. SDS-Page gels
(12%) were prepared and marker plus proteins were loaded onto
the gels. After running the gels, proteins were transferred onto
nitrocellulose membranes with an iBlot apparatus (Invitrogen).
After transferring the proteins, blots were blocked with 5% milk
proteins in Tris-buffered Saline (TBS) with 0.1% tween-20 (Invi-
trogen) for at least 1 h at room temperature. Next, blots were
washed in TBS-T (TBS containing 0.1% tween-20) and incubated
overnight on the roller mixer at room temperature in TBS-T con-
taining primary antibody against IL-32 (AF3040, R&D Systems), at a
concentration of 0.2 mg/ml, or against ApoA1 (Acris Antibodies
GmbH, Herford, Germany), at a concentration of 1.0 mg/ml. The
following day, blots were washed with TBST and the IL-32 blots
were incubated with rabbit-anti-mouse-HRP (Dako P0449, 1:5000
in TBST) while the ApoA1 blots were incubated with rabbit-anti-
mouse-HRP (Dako P0260, 1:5000 in TBST) and incubated for 1 h
at room temperature on the roller mixer. Next, blots were washed
and incubated with ECL (GE Health care Life Sciences) before
scanning the blots. Finally, actin was detected on the blots by using
anti-actin antibodies (Santa Cruz Biotechnology) and appropriate
secondary antibody (Dako) followed by ECL incubation and scan-
ning of the blots.
2.4. IL-32 ELISA
Maxisorp plates (Nunc) were coated with AF3040 (R&D Sys-
tems) diluted in Phosphate Buffered Saline (PBS) at a concentration
of 0.4 mg/ml and incubated overnight at room temperature. Next
morning, plates were blocked with PBS containing 1% BSA (Sigma-
Aldrich) for 1 h at room temperature. Standard curve was prepared
by diluting recombinant IL-32 ranging from 5000 pg/ml until
39.06 pg/ml in PBS containing 5% BSA. Standard curve was added
followed by the supernatant samples from the primary liver cells.
ELISA plates were incubated for 2 h on a shaker. After the incuba-
tion, plates were washed and detection antibody was added
(BAF3040, R&D Systems), 0.1 mg/ml in PBS with 5% BSA. Plates were
incubated for 1 h at room temperature on the shaker. Subsequently,
plateswerewashed and streptavidin (R&D Systems) was added and
the plates were incubated for 30min at room temperature on the
shaker. After the last incubation, plates were washed and substrate
buffer was added and the color reaction was closely monitored
until the reaction was terminated by adding stop solution. Finally,
the plates were read by a plate-reader and IL-32 concentrations
were calculated.
2.5. Overexpression of IL-32 in HepG2 cell line
Half million HepG2 cells were seeded per well in a 24-well plate
in RPMI-1640 including 5% FCS and incubated overnight at 37 C
and 5% CO2. The following day, medium was replaced by the same
fresh medium and transfection medium containing IL-32 plasmids
(pCDNA3-IL32a, pCDNA3-IL32b, pCDNA3-IL32g) or a control
plasmid (pCDNA3-eGFP) was prepared. Transfection medium per
transfectionwas prepared as follow; 1) dissolve 0.5 mg plasmid DNA
in 25 ml serum free RPMI-1640, 2) add 1.5 ml Fugene HD (Promega)
directly to the DNAmixture, 3) vortex 1e2 s and incubate for 15min
at room temperature, 4) add 25 ml dropwise per well while gently
shaking the plate, 5) incubate for 24 or 48 h at 37 C and 5% CO2.
After the incubation, RNA and protein samples were isolated for
determining gene expression and IL-32 protein expression as pre-
viously described.
2.6. BODIPY ﬂowcytometry assay
Transfected HepG2 cells and THP-1 cells were used for the
BODIPY FACS analysis. Inmore detail, 1 million (HepG2) or 2.5 105
(THP-1) cells per well were used for the transfection after which
cells were detached, spun down and resuspended in PBS containing
4% Formaldehyde (FA) for 15min on ice. Thereafter, the cells were
spun down again and resuspended in PBS with 5% BSA and BODIPY
(1:500) for 45min on ice in the dark, after which the BODIPY signal
was measured.
2.7. Overexpression and silencing of IL-32 in THP1 cells
THP-1 cells (15 106 cells/15mL) were differentiated into mac-
rophages (75 cm2 e tissue culture ﬂask; Corner) in RPMI-1640
including 10% FCS, PMA (Sigma-Aldrich) at 10 ng/ml, b-mercap-
toethanol (Sigma-Aldrich) at 50 mM and incubated for 48 h at 37 C
and 5% CO2. 2.5 106 cells/800 mL were electroporated with Amaxa
Nucleofactor technology (Lonza, Basel), according with the protocol
described in [35]. For IL-32 knockdown, 1 mg of ON-TARGETplus
SMARTpool siRNA per transfection was used or 1 mg of ON-
TARGETplus SMARTpool control siRNA (Dharmacon Inc.), se-
quences are described in [36]. For IL-32 overexpression, 0.5 mg of
pCDNA3 plasmid expressing human IL-32g of eGFP was used as
control. Transfected cells (3 105/100 mL) were plated on ﬂat-
bottom 96-well plates (Costar) and 100 mL of transfection me-
dium was added. After 4 and 24 h, the cell monolayers were
collected by adding 200 mL of TRIzol and stored at 80 C until
mRNA extraction. Comparable studies were performed to deter-
mine transfection (eGFP) efﬁciency, which was around 30%.
2.8. Foam cell formation of THP-1 cells and human derived percoll
monocytes
THP-1 cells (15 106 cells/15mL) were differentiated into mac-
rophages (75 cm2 e tissue culture ﬂask; Corner) in RPMI-1640,
including 10% FCS, PMA (Sigma-Aldrich) at 10 ng/mL, b-mercap-
toethanol (Sigma-Aldrich) at 50 mM, and incubated for 48 h at 37 C
and 5% CO2. 5 105 cells per well were seeded in 24wells plate and
starved for 4 h in RPMI-1640 supplemented 2mML-glutamine,
1mM pyruvate and 50 mg/ml gentamicin (GIBCO Invitrogen,
Carlsbad, CA), after which oxidized LDL was added (25mg/mL) for
24 h at 37 C and 5% CO2. Human pheripheral blood mononuclear
cells were isolated by density centrifugation over Ficoll-Paque.
Next, Percoll isolation of monocytes was performed as previously
described [37]. In brief, 150-200  106 PBMCs were layered on top
of a hyper-osmotic Percoll solution and centrifuged for 15 min at
580g. The interphase layer was isolated and cells werewashed with
cold PBS. Cells were resuspended in RPMIþþþ. An extra puriﬁca-
tion step was added by adhering Percoll isolated monocytes to
polystyrene ﬂat bottom plates (Corning, NY, USA) for 1 h at 37 C
and 5% CO2; subsequently, a washing step with warm PBS was
performed to yield maximal purity. Once Percoll monocytes were
obtained, they were differentiated into macrophages for 6 days in
10% human pool serum. On day 6, medium was removed and cells
were starved for 4 h, similar to the THP-1 cells, before being fed
oxidized LDL for 24 h. After 24 h, supernatants were collected and
cells were stored in TRIzol reagent for mRNA isolation.
2.9. Statistics
Statistical analysis were performed with the Mann-Whitney U
test, Spearman correlation test or One-way Anova including
Kruskal-Wallis test and Dunn's Multiple comparison test. In each
ﬁgure, the applied statistical test is indicated.
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3. Results
3.1. Induction of IL-32 isoforms in human primary liver cells by
TNFa or TLR3 ligand poly I:C
Primary liver cells were stimulated with recombinant human
TNFa (rhTNFa) or Poly I:C to studywhether these cells were capable
of expressing IL-32. Stimulation of cells with rhTNFa resulted in a
slight upregulation of IL-32amRNA expression (Fig. 1A). Moreover,
the protein level of IL-32b was determined intracellularly and was
induced mostly by rhTNFa, but also Poly I:C stimulation (Fig. 1D
and E). Poly I:C stimulation resulted in a slight increase in IL-32g
mRNA expression but almost no to minor increase in either IL-32b
or IL-32a, respectively, compared to medium control (Fig. 1AeC).
Furthermore, Poly I:C stimulation resulted in higher extracellular
IL-32 protein levels (Fig. 1F).
3.2. Induction of IL-32 in human primary liver cells leads to
enhanced expression of important regulators of cholesterol
homeostasis which correlate strongly with IL-32g mRNA expression
Here, we explored whether TNFa- or TLR3-poly I:C-induced IL-
32 expression in human primary liver cells modulates the expres-
sion of cholesterol transporters and regulators of cholesterol ho-
meostasis. Furthermore, we studied whether there was a
correlation between mRNA expression of IL-32 isoforms and the
components involved in the cholesterol homeostasis. As shown in
Fig. 2AeD, stimulation of human primary liver cells with poly I:C
resulted in increased expression of ABCA1, ABCG1, ApoA1 and LXRa
mRNA. Besides mRNA levels, protein levels of ApoA1 were also
studied and showed to be increased after stimulation with poly I:C,
and possibly after rhTNFa stimulation (Fig. 2E and F). As a positive
control to study the function of the cells, we determined the
rhTNFa- and poly I:C-induced IL-8 mRNA expression in liver cells
(Supplementary Fig. 1A). Additionally, a strong positive correlation
between the IL-32g isoform and ABCA1, ABCG1, ApoA1 and LXRa
expression was observed after the cells were stimulated with poly
I:C (Fig. 2FeI). Cells stimulated with rhTNFa also showed positive
correlations to the same mediators (Supplementary Figs. 1BeE).
These correlations were not observed when looking at IL-32a nor
IL-32b expression and these mediators (Supplementary Table 1).
3.3. Endogenous expression of IL-32g and ABCA1 mRNA in HepG2
cells
To further study the effect of IL-32 isoforms on the expression of
cholesterol mediators, a human liver cell line was used (HepG2 cell
line) (Fig. 3AeD). At ﬁrst, unstimulated HepG2 cells were studied to
look at the basal mRNA expression levels of IL-32 and cholesterol
mediators. Similar to the observation made in human primary liver
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Fig. 1. Induction of IL-32 expression in human primary liver cells.
(A) Stimulation with TNFa induced signiﬁcant expression of IL-32a (n¼ 7, Mann-Whitney U test, p¼ 0.0070). (B) Signiﬁcant differences between TNFa and Poly I:C induced IL-32b
(n¼ 7, Mann-Whitney U test, p¼ 0.0023). (C) Poly I:C stimulation enhanced the expression of IL-32g both compared with medium control (n¼ 7, Mann-Whitney U test, p¼ 0.0111)
and TNFa (n¼ 7, Mann-Whitney U test, p¼ 0.0070). (D) Induction of IL-32b protein by TNFa or Poly I:C in primary liver cells from 3 donors (actin as loading control). (E) Relative
expression of L-32b protein corrected for actin expression after stimulation (med, TNFa, Poly I:C). (F) IL-32 protein expression after TNFa and Poly I:C stimulation in culture su-
pernatants of human primary liver cells (n¼ 5 (with replicates), Mann-Whitney U test, medium vs. Poly I:C p¼ 0.0176; TNFa vs. Poly I:C p¼ 0.0471).
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cells, also HepG2 cells showed expression of the three isoforms of
IL-32 (IL-32a, IL-32b and IL-32g) and ABCA1 (Fig. 3AeD). Interest-
ingly, IL-32g expressionwas already upregulated after 4 h of culture
in only DMEM complete medium with 10% FCS hi, together with
ABCA1 expression, while IL-32a did not showany expression and IL-
32b only minor expression (Fig. 3A and B). As shown in Fig. 4A and
B, the relative expression of IL-32a and IL-32b increased after 24 h,
but resulted in an even more pronounced expression after 48 h of
culture.Within the same time, expression of both IL-32g and ABCA1
decreased (Fig. 3C and D). Highly interesting, a positive correlation
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Fig. 2. Induction of cholesterol transporters ABCA1/ABCG1, HDL particle ApoA1 and transcription factor LXRa in human primary liver cells, and their correlation with IL-32g after
Poly I:C stimulation of cells for 24 h.
(A) Stimulation with Poly I:C signiﬁcantly induced ABCA1 (n¼ 7, Mann-Whitney U test, medium vs. Poly I:C p¼ 0.0041; TNFa vs. Poly I:C p¼ 0.011). (B) ABCG1 expression was
signiﬁcantly induced by Poly I:C (n¼ 7, Mann-Whitney U test, medium vs. Poly I:C p¼ 0.0023; TNFa vs Poly I:C p¼ 0.0262). (C) HDL particle ApoA1was signiﬁcantly induced by Poly
I:C (n¼ 7, Mann-Whitney U test, medium vs. Poly I:C p¼ 0.0260; TNFa vs. Poly I:C p¼ 0.0411). (D) Poly I:C stimulation signiﬁcantly induced the transcription factor LXRa (n¼ 7,
Mann-Whitney U test, medium vs. Poly I:C p¼ 0.0023; TNFa vs. Poly I:C p¼ 0.0262). (E) Induction of ApoA1 protein after Poly I:C stimulation in 2 different donors. (F) Relative
expression of ApoA1 protein corrected for actin expression in two donors. (G) Positive correlation between IL-32g and ABCA1 (Spearman r¼ 0.4727, p¼ ns). (H) Positive correlation
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between IL-32g and ApoA1 (Spearman r ¼ 0.9455, p < 0.0001***). All graphs show the relative mRNA expression adjusted for GAPDH expression. (n ¼ 5, data includes replicates).
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between IL-32 isoforms and ABCA1 expression was again mostly
observed for the IL-32g isoform (Fig. 3E and Supplementary Fig. 2).
3.4. Overexpression of IL-32a, IL-32b or IL-32g results in strong
induction of cholesterol transporters and reduced intracellular lipid
concentrations in HepG2 cells
Since we noted strong correlations between mRNA expression
of IL-32 isoforms and cholesterol transporters, we were interested
in the function of these cholesterol transporters in the presence of
IL-32. HepG2 cells were therefore transfected with pCDNA3 con-
structs containing either eGFP (as a negative control), IL-32a, IL-32b
or IL-32g. As shown in Fig. 4A, overexpression of the various iso-
forms of IL-32 resulted in protein expression of that speciﬁc isoform
after 48 h of transfection. Moreover, overexpression of the IL-32a
isoform resulted in a trend towards an increased expression in LXRa
and ABCA1 (Fig. 4B and C). Additionally, overexpression of the IL-
32b and IL-32g isoforms resulted in an increased expression of LXRa
(non-signiﬁcant for IL-32g), ABCA1 and ABCG1 (Fig. 4BeD). How-
ever, important mediators such as ApoA1 (mRNA and protein) and
SR-B1 (mRNA) were not affected in HepG2 cells overexpressing the
isoforms of IL-32 (Supplemental Fig. 3). Finally, we performed a
boron-dipyrromethene (BODIPY) staining to study the intracellular
lipid content of the transfected versus untransfected HepG2 cells.
BODIPY ﬂuorescence was signiﬁcantly lower in HepG2 cells trans-
fected with the IL-32b isoforms and showed a trend towards lower
expression in IL-32a and IL-32g transfected compared to the
untransfected control or eGFP transfected negative control (Fig. 4E).
The strongest reduction of BODIPY was observed after transfection
of HepG2 cells with IL-32b.
3.5. Silencing of IL-32g strongly reduces ABCA1 mRNA expression
As described above, overexpression of the IL-32g isoform in
HepG2 liver cells resulted in an increased expression and possible
function of ABCA1. To study the role of IL-32g into more detail, we
studied IL-32g and ABCA1 expression in carotid artery plaque tis-
sue and performed knockdown experiments of IL-32g. Due to the
fact that HepG2 cells did not survive the procedure to knockdown
IL-32g, we were prompted to use another cell line. We performed
silencing and overexpression experiments in a human monocytic
cancer cell line (THP1 cell line). This because ABCA1 expression and
function is also very important for monocytes in the circulation,
contributing to reverse cholesterol transport. Using THP1 cells, IL-
32g overexpression resulted in high expression of IL-32g as well as
ABCA1 (Fig. 5A and D).When IL-32gwas silenced, IL-32g and ABCA1
expression was completely diminished (Fig. 5B and E). This effect
was not caused by the transfection method itself, since THP1 cells
transfected with eGFP or spC negative controls did not result in
these effects on ABCA1 expression (Fig. 5A, B, D and E). The spIL-32
construct is also capable of silencing other isoforms of IL-32 as is
shown by the silencing of IL-32b (Fig. 5C). Besides, since we
observed similar expression patterns of induced cholesterol
transporters in THP-1 cells, we performed overexpression experi-
ments in THP-1 cells to do the BODIPY staining. Overexpressing IL-
32g in THP-1 cells resulted in a decrease of BODIPY ﬂuorescence
(Supplementary Fig. 4). Moreover, after observing the importance
of IL-32g on ABCA1 expression in liver cells and THP-1 cells, we
were curious if this effect was also present in plaque tissue inwhich
ABCA1 expression can affect foam cell formation. We were able to
show an increased expression of IL-32g and ABCA1mRNA in carotid
artery plaque tissue (Fig. 5F and G). Finally, THP-1 derived macro-
phages and human derived percoll monocytes (differentiated to
macrophages) were loaded with oxidized LDL (25 mg/mL, 50 mg/mL,
respectively) for 24 h to study the expression of IL-32 isoforms and
mediators involved in cholesterol metabolism in foam cells. Inter-
estingly, IL-32 isoform expression of IL-32a, IL-32b and IL-32g
seemed to be decreased or unchanged compared to normal mac-
rophages (Supplementary Fig. 5). Nevertheless, cholesterol medi-
ators ABCA1, ABCG1 and LXRa seemed to be induced, albeit not
signiﬁcantly (Supplementary Fig. 5).
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Fig. 3. Time-dependent induction of IL-32g and cholesterol transporter ABCA1 in
human HepG2 cells.
(A) Expression of IL-32a is signiﬁcantly induced after 48 h compared with 24 h, while
at 4 h, the expression of IL-32a was not detectable (4 replicates, Mann-Whitney U test,
p¼ 0.0286). (B) Expression of IL-32b was already detected at 4 h and signiﬁcantly
enhanced after 24 h and after 48 h (4 replicates, Mann-Whitney U test, p¼ 0.0286). (C)
Expression of IL-32g was already high at 4 h and decreased after 24 h and 48 h (4
replicates, Mann-Whitney U test, p¼ 0.0286). (D) Expression of the cholesterol
transporter ABCA1 was high at 4 h and signiﬁcantly decreased after 24 h and 48 h (4
replicates, Mann-Whitney U test, p¼ 0.0286). (E) Correlation between IL-32g and
ABCA1 at different time points showed to be highly signiﬁcant p< 0.0001, with a
Spearman r of 0.9580. All conditions were kept in DMEM complete medium with 10%
fetal calf serum heat-inactivated. Time course started after plating the cells.
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Fig. 4. Modulation of transcription factor LXRa and cholesterol transporters ABCA1/ABCG1 resulted in lower intracellular lipid content after IL-32 overexpression in human HepG2
cells.
(A) Overexpression of different IL-32 isoforms in human HepG2 liver cells at 24 h and 48 h. IL-32a (approx. 19 kDa), IL-32b (approx. 26 kDa), IL-32g (approx. 29 kDa). (B) Tran-
scription factor LXRa was signiﬁcantly induced after overexpression of IL-32b (5 replicates, Mann-Whitney U test, p¼ 0.0317). (C) Overexpression of IL-32a (p¼ 0.0317), IL-32b
(p¼ 0.0159), IL-32g (p¼ 0.0159) signiﬁcantly induced ABCA1 expression (5 replicates, Mann-Whitney U test). (D) Overexpression of IL-32b and IL-32g enhanced the expression of
ABCG1 (5 replicates, Mann-Whitney U test, p¼ 0.0079). (E) Mean ﬂuorescent intensity was signiﬁcantly reduced after overexpression of IL-32b (4 replicates, Mann-Whitney U test,
p¼ 0.0286). Replicates are from 2 independent experiments with technical replicates within each experiment.
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4. Discussion
In the present study, we aimed to investigate the effect of IL32
on proteins involved in cholesterol metabolism in liver cells and
atherosclerotic plaques.We show for the ﬁrst time that both human
primary liver cells and a HepG2 cell line express IL-32 mRNA and
protein and that human carotid artery tissue expresses IL-32g
mRNA. Moreover, the three main IL-32 isoforms, IL-32g, IL-32b and
IL-32a, can be induced either by recombinant human (rh)TNFa or a
synthetic analogue of a double-stranded RNA virus (Poly I:C)
stimulation in these liver cells. mRNA expression of components
important in cholesterol metabolism, such as, ABCA1, ABCG1, LXRa
and apoA1, are correlated to expression levels of IL-32g isoforms in
unstimulated human primary liver cells and HepG2 cells. Addi-
tionally, overexpression of IL-32b and IL-32g resulted in induction
of ABCA1 and ABCG1 in HepG2 cells and overexpression of IL-32g
induction of ABCA1 expression in THP-1 cells. By performing the
BODIPY ﬂowcytometry assay, we could show that in the presence of
endogenous IL-32, intracellular lipid concentrations were
decreased. Moreover, silencing of IL-32 in THP-1 cells caused a
strong reduction of ABCA1 expression. Lastly, we also observed
increased mRNA expression of IL-32 and ABCA1 in human carotid
artery tissue obtained from carotid endarterectomy surgery.
A recent study suggested the existence of an association be-
tween IL-32 and HDL cholesterol, which can become relevant for
patients with an increased risk to develop CVD, such as RA patients.
A single nucleotide polymorphism (SNP) in the promoter region of
IL32 was described to be correlated with higher HDLc concentra-
tions in RA patients, suggesting a possible role for IL-32 in deter-
mining CVD risk [18]. Moreover, this SNP possibly results in more
IL-32 protein expression [38]. This suggests higher IL-32 protein
concentrations are linked with higher HDLc concentrations.
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Fig. 5. IL-32 regulates cholesterol transporter ABCA1 in THP1 cells and is expressed in human carotid artery plaque tissue.
(A) Human THP1 cells transfected with different plasmids (pCDNA3-eGFP or pCDNA3-IL32g) or no plasmids (wt control) showed signiﬁcant induction of IL-32gwhen the cells were
transfected with pCDNA3-IL32g (p < 0.05* or p < 0.01**). 6 replicates, One-Way ANOVA, Kruskal test, Dunn's Multiple Comparison Test. (B) Silencing of IL-32g showed signiﬁcant
reduction of IL-32g expression compared to the wt control or smartpool-control (6 replicates, One-Way ANOVA, Kruskal-Wallis test, Dunn's Multiple Correction Test). (C) Silencing
of IL-32b showed signiﬁcant reduction of IL-32b expression compared to the wt control or smartpool-control (6 replicates, One-Way ANOVA, Kruskal-Wallis test, Dunn's Multiple
Correction Test). (D) Overexpression of IL-32g induced signiﬁcant expression of ABCA1. (E) Silencing of IL-32g downregulated ABCA1 signiﬁcantly in THP1 cells. (F) Human carotid
artery plaque tissue showed induced expression of IL-32g mRNA compared to healthy tissue (p ¼ 0.0017*). (G) Human carotid artery plaque tissue showed induced expression of
ABCA1 mRNA compared to healthy tissue (p ¼ 0.0124*).
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Next to IL-32 mRNA and protein, we also studied the expression
of various cholesterol transporters/mediators involved in choles-
terol metabolism such as, ABCA1, ABCG1, ApoA1 and LXRa. Tight
regulation of low-density lipoprotein (LDL) and high-density lipo-
protein (HDL) cholesterol is important to prevent cardiovascular
disease, such as atherosclerosis. Circulating HDLc concentrations
are regulated by biosynthesis and degradation processes in which
the liver plays an important role [22]. HDL biosynthesis is regulated
by the production and secretion of apoA-I by the liver and lip-
idation of these apolipoproteins by ABCA1 transporters expressed
on liver cells [23]. Expression of this cholesterol transporter ABCA1
in hepatocytes plays an important role in the biosynthesis and
regulation of circulating HDL cholesterol [26,39,40]. Furthermore,
enterocytes are also involved in the biosynthesis and maintenance
of HDL. Via a complex network of cholesterol transporters, the
small intestine establishes a balance between the amount of
excreted and absorbed cholesterol and in that way inﬂuences RCT
[41,42]. Moreover, downregulating absorption of cholesterol in the
intestine has been shown to improve RCT [41]. Besides, degradation
of HDLc is regulated by different pathways. One way the body can
get rid of circulating HDLc is by uptake of HDLc via the SR-B1
transporter on liver cells. An alternative pathway is the degrada-
tion of HDLc by CETP. A third way HDLc can be affected is by
catabolism in the kidney via cubilin endocytosis and SRB1 in the
proximal tubulus of the kidney. HDLc will be reabsorbed and
degraded mostly via SRB1 whereas cubulin and megalin endocy-
tose essentially lipid-free apoA-I [43,44]. These changes in HDL
composition occur during the important RCT pathway. Excessive
cholesterol is transported from the peripheral tissues, such as the
vessel wall, back to the liver for excretion, preventing atheroscle-
rosis. During RCT, accumulated cholesterol from macrophages in
the vessel wall is removed to HDL or lipid-poor apolipoprotein
(apo)A1 by different mechanisms, including one which is depen-
dent on the cell membrane expression of ABCA1 on macrophages
[45,46]. Upregulation of ABCA1 would therefore favour an anti-
atherogenic environment whereas downregulation of ABCA1
could create an atherogenic state by reducing cholesterol efﬂux and
HDLc concentrations. The aim of the study was to understand the
mechanism behind the regulation of HDLc concentrations by IL-32.
Our results show that induction of IL-32g is correlated with
induced ABCA1 mRNA expression in unstimulated human primary
liver cells and HepG2 cells. IL-32b expression did not show any
correlation and IL-32a even showed a negative correlation with
ABCA1, ABCG1 and LXRa mRNA expression. Additionally, over-
expression experiments of IL-32 isoforms in HepG2 cells showed
that IL-32b and IL-32g are associated with upregulation of ABCA1
and ABCG1. Due to the fact that HepG2 cells were no longer viable
after knocking down IL32, overexpressing and silencing experi-
ments of IL-32g were performed in THP1 macrophages. In the
presence or absence of IL-32g, ABCA1 expression was strongly
induced or reduced, respectively. This deﬁnitely demonstrated that
IL-32g is a key player in driving ABCA1 expression. We suggest that
this effect is most likely caused by the direct regulation of LXRa
expression by IL-32. LXRa is known to mediate, at least partially,
the expression of ABCA1 [47]. Furthermore, we show that the most
potent isoform of IL-32, IL-32g, together with ABCA1, ABCG1 and
LXRa, is also strongly upregulated by Poly I:C stimulation of pri-
mary liver cells and HepG2 cells. These data are conﬂicting with
previous data by Castrillo A et al., who showed that LXRa and
ABCA1 are inhibited after activation of Toll-like receptors (TLRs) 3
and 4 by microbial ligands like viruses or bacteria [48]. One
explanation for this could be the fact that two completely different
cell types are used in our experiments compared to the macro-
phages used in Castrillo's experiments. Moreover, it is possible that
stimulation of hepatocytes with a viral component such as poly I:C
could trigger a slightly different intracellular pathway or the
expression of IL-32 in these cells is of more importance and
therefore results in different effects in various cell types.
Besides, the changes we found on cholesterol transporters
expression seem functional, since intracellular lipid concentrations
were lower in cells overexpressing IL-32 isoforms. These data show
a completely new function of endogenous IL-32 in liver cells and
THP-1 derived macrophages even suggesting a possible anti-
atherosclerotic function for the pro-inﬂammatory cytokine. How-
ever, when studying THP-1 macrophage foam cells or foam cells
generated from human percoll monocytes differentiated to mac-
rophages, isoforms of IL-32 were reduced or unchanged and only
ABCA1, ABCG1 and LXRawere induced. This might be explained by
the fact that oxidized LDL is taken up by different receptors such as
CD36 and scavenger receptor A which could result in a different
intracellular signal cascade compared to poly I:C stimulation or
overexpressing experiments [49]. Another explanation for the new
link between IL-32 and ABCA1 could be explained by the fact that
ABCA1 also has other important functions besides regulating HDL
cholesterol. Previous studies showed that intracellular cholesterol
homeostasis was required for a housekeeping function of cells.
Additionally, recent studies indicated that cholesterol regulation,
more speciﬁcally sterols, are dynamically regulated, bioactive and
are intrinsic players in the immune response that couples meta-
bolism to host defence [50]. The question whether IL-32 is anti- or
pro-atherogenic is still difﬁcult to answer. For now, we can
conclude that IL-32 has many pro-inﬂammatory/pro-atherogenic
capacities but that this study shows that IL-32g closely associates
with ABCA1 and other cholesterol mediators and in that way serves
as an anti-atherogenic mediator.
Some limitations could be envisaged in our study. One of these
limitations could be the fact we did not measure HDL functionality
but only HDLc concentrations even though previous studies have
showed functionality being more important than HDL cholesterol
concentration in determining cardiovascular disease risk [19,51].
Furthermore, additional experiments could not be performed due
to lack of sample since all samples were used for the initial
experiments.
To conclude, the present study shows for the ﬁrst time the ex-
istence of a direct association between IL-32 and cholesterol ho-
meostasis in humans. We provide clear and novel evidence that IL-
32 is an important regulator of cholesterol transporters ABCA1 and
ABCG1, possibly explaining the variation of HDLc concentrations
previously observed in individuals bearing a SNP in IL-32 gene.
Whether these interactions would further translate into a higher or
lower CV risk remains to be elucidated in future studies, as well as
the gain of more knowledge and understanding of the complex
interactions between inﬂammatory effectors, lipids homeostasis
and atherosclerosis.
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